Cohort plc (AIM: CHRT)

London flag London · Delayed Price · Currency is GBP · Price in GBX
1,153.20
-6.80 (-0.59%)
Jan 22, 2025, 8:54 AM GMT+1
109.67%
Market Cap 524.13M
Revenue (ttm) 226.47M
Net Income (ttm) 19.40M
Shares Out 45.18M
EPS (ttm) 0.48
PE Ratio 24.40
Forward PE 25.29
Dividend 0.15 (1.32%)
Ex-Dividend Date Jan 9, 2025
Volume 1,802
Average Volume 101,945
Open 1,200.00
Previous Close 1,160.00
Day's Range 1,153.20 - 1,200.00
52-Week Range 520.00 - 1,230.00
Beta 0.52
RSI 61.51
Earnings Date Mar 13, 2025

About Cohort

Cohort plc provides a various products and services in defense, security, and related markets in the United Kingdom, Germany, Portugal, Africa, North and South America, and the Asia Pacific and Africa, and other European countries. It operates through Communications and Intelligence; and Sensors and Effectors segments. The company offers chess dynamic, a surveillance and fire control, such as command, control, communications, computers, intelligence, surveillance, target acquisition, and reconnaissance, as well as combat systems. It provides in... [Read more]

Sector Industrials
Founded 2006
Employees 1,309
Stock Exchange London Stock Exchange AIM
Ticker Symbol CHRT
Full Company Profile

Financial Performance

In 2024, Cohort's revenue was 202.53 million, an increase of 10.85% compared to the previous year's 182.71 million. Earnings were 15.32 million, an increase of 34.87%.

Financial Statements

News

U.S. Global Launches Technology And Aerospace & Defense ETF: Why Its Allocation Makes Sense

The launch of the U.S. Global Technology and Aerospace & Defense ETF (NYSE: WAR) on Dec. 30, 2024, and its subsequent debut on the New York Stock Exchange, is another feather in the cap for U.S. Glob...

19 days ago - Benzinga

Half Year 2025 Cohort PLC Earnings Presentation Transcript

Half Year 2025 Cohort PLC Earnings Presentation Transcript

5 weeks ago - GuruFocus

Half Year 2025 Cohort PLC Analyst presentation Q&A Transcript

Half Year 2025 Cohort PLC Analyst presentation Q&A Transcript

5 weeks ago - GuruFocus

Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients

Theriva Biologics announces DSMC approval to proceed to Cohort ... Full story available on Benzinga.com

3 months ago - Benzinga

Hub71 welcomes 21 startups in 15th Cohort to Abu Dhabi that have raised over $130mln in funding

Cohort 15 startups have raised over USD 130 million in capital, with 80 per cent of selected startups headquartered outside the UAE, reinforcing Hub71's ability to attract high-potential international...

4 months ago - Zawya